Bristol/ImClone Erbitux BLA Resubmission Expected During First Quarter
Executive Summary
ImClone expects to resubmit the BLA for Erbitux (cetuximab) during the first quarter after addressing the issues raised in FDA's "refuse-to-file" letter for the colorectal cancer treatment
You may also be interested in...
Amgen As Model For Corporate Governance: CEO Says Ignorance Is No Excuse
CEOs should not be permitted to argue that they are ignorant of ethical deviations within their companies, Amgen CEO Kevin Sharer declared Jan. 14 during the J.P. Morgan health care conference in San Francisco
Bristol Erbitux: Colorectal Refiling Within 9 Months; Broader Package In 2004
Bristol-Myers Squibb could refile Erbitux in irinotecan-refractory colorectal cancer by July, Exec VP Donald Hayden told the Bear Stearns healthcare conference in New York City Sept. 17
Bristol Erbitux: Colorectal Refiling Within 9 Months; Broader Package In 2004
Bristol-Myers Squibb could refile Erbitux in irinotecan-refractory colorectal cancer by July, Exec VP Donald Hayden told the Bear Stearns healthcare conference in New York City Sept. 17